SPAIN’S Rovi to start manufacturing an active ingredient of the Moderna Covid vaccine in Andalucía
In a further boost to Spain’s vaccination drive which aims to inoculate 70 per cent of the adult population by the summer, Laboratorios Farmaceuticos Rovi has announced that it will begin to manufacture the active ingredient of the Moderna Covid jab in its warehouse in Granada in the Andalucían Community. Consequently, shares in Rovi have jumped by a healthy 4.23 per cent to €48.10 on Monday, April 12, following the announcement.
The refurbished facility in Granada will be able to produce more than 100 million doses of the Moderna jab per year, and it is hoped that it will begin supplying the European market by the third quarter of 2021.
“We are very happy for the collaboration with Moderna, whose vaccine against Covid-19 is one of the best positioned in the race to solve this health crisis. We are very excited that Rovi is going one step further and participating in the manufacture of the active principle of the vaccine, since greater integration in the production process would allow us to support Moderna in its large-scale supply more widely”, the CEO of Rovi, Juan López-Belmonte Encina, told Spanish daily Granadahoy.
“Our proven experience and capabilities as a manufacturer of injectables for third parties of high technological value have allowed us to reinforce the current agreement with Moderna, which would contribute to the strengthening of our manufacturing area, predictably providing us with an opportunity for significant growth in this area”, he added.
The Government’s estimated figure is that Spain will be able to supply as many as 8.1 million injectables per month during the spring, and the following months up until September, at which rate it will not be a problem to inoculate the 33 million people required to achieve the proposed ‘herd immunity’.